Mindset Pharma to Participate in Citi’s Psychedelic Drug Call Series on January 6th
Mindset Pharma (OTCQB: MSSTF), a drug discovery company focused on developing next-generation psychedelic medicines, will participate in the Citi Psychedelic Drug Call Series on January 6, 2022. CEO James Lanthier and CSO Joseph Araujo will engage in a fireside chat. Additionally, the team will attend the 40th Annual J.P. Morgan Healthcare Conference from January 10-12, 2022, in San Francisco. Mindset is dedicated to addressing neurological and psychiatric disorders through innovative psychedelic compounds.
- None.
- None.
TORONTO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it will participate in Citi’s Psychedelic Drug Call Series to be held virtually on Thursday, January 6, 2022.
Neena Bitritto-Garg, Citi’s Biotech analyst, will host James Lanthier, CEO of Mindset, and Joseph Araujo, CSO of Mindset, for a fireside chat at 10:00 a.m. ET.
For more information about the event, please contact your appropriate Citi representative directly.
Additionally, Mindset's management team will be available to participate in investor and partnering meetings surrounding the 40th Annual J.P. Morgan Healthcare Conference to be held January 10-12, 2022, in San Francisco, CA. To schedule a one-on-one meeting, please send an email to KCSA Strategic Communications at MindSet@kcsa.com.
About Mindset Pharma
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
For further information on Mindset, please visit our website at www.mindsetpharma.com.
For more information, please contact:
Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com
Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094
Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized bywords such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FAQ
What is the purpose of Mindset Pharma's participation in the Citi Psychedelic Drug Call Series on January 6, 2022?
Who will represent Mindset Pharma at the Citi event on January 6, 2022?
What major conference will Mindset Pharma attend in January 2022?
How can investors schedule a meeting with Mindset Pharma during the J.P. Morgan Healthcare Conference?
What is Mindset Pharma's focus in drug discovery?
